Say Hello!
Don’t be shy.

 
0333 323 1843
 

[email protected]

 

BioCity Group HQ:
Pennyfoot Street
Nottingham
NG1 1GF

BioCity sponsors Medlink East Midlands Business Awards Deal of the Year

BioCity sponsors Medlink East Midlands Business Awards Deal of the Year

Medilink East Midlands Business Awards: Deal of the Year Award

It’s an old cliché that money makes the world go round, but nevertheless, financial deals are an important aspect of business. Life Sciences are no different and deals are exciting catalysts for change and growth. Here at Medilink East Midlands, we recognise this and have teamed up with the BioCity Group, to deliver the Deal of the Year Award.

This is for entrepreneurship of an individual or team in executing a truly transformational and high value deal for both the company and the East Midlands Life Sciences sector.

The finalists in this category are:

Nikin Patel and his team

(Sale of Juniper Pharmaceuticals to Catalent)

Juniper Pharmaceuticals grew significantly between 2014-2018, increasing its staff-count from 60 to 200 and increasing the value of Juniper’s Nottingham operations from $25million to $140million in this period.

Although the outcome of the deal was ultimately determined by the board of directors, which included Nikin, it was Nikin and his team who saw through the execution of the deal itself.

Mark Egerton and his team at Quotient Sciences

By the summer of 2018, Quotient looked to find a new private equity partner to support its future growth aspirations.This resulted in a comprehensive and competitive process to identify a new partner. This was undertaken by Quotient’s CEO Mark Egerton and his team.

Permira was selected on the basis of their insight into Quotient Sciences and their commitment to support Quotient’s management team to grow the business organically.

Simon Hirst and his team at Sygnature Discovery

Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services company with a global client base including major pharmaceutical and top biotech companies.  Fourteen potential new medicines have originated from Sygnature which are undergoing clinical evaluation.

The decision by Sygnature to acquire RenaSci in July 2018 arose out of a number of joint client-related scientific collaborations.  Sygnature’s view was that combining the two organisations would provide greater benefit to both Sygnature’s and RenaSci’s customers and ultimately to patients. Building on their existing relationship, the deal took six months to complete with Sygnature acquiring 100% of the share capital in RenaSci, whilst retaining RenaSci as a separate company and brand within the Sygnature Group.

Toby Reid, Chief Executive Officer at BioCity Group, said:

“As a home to dynamic, high-growth businesses, we are proud sponsors of the Deal of the Year category. We are privileged to work with many innovative and entrepreneurial businesses in the region and it is fantastic to recognise not only those businesses but also the inspirational individuals who lead those organisations to success.”

To see the Medilink East Midlands website for the other award categories, click here.

The awards will be presented on Thursday 5 December at the Radisson Blu, East Midlands Airport.